Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Core Insights - Teva Pharmaceutical Industries Limited has entered the acceleration phase of its "Pivot to Growth" strategy after successfully completing the initial phase, which has led to nine consecutive quarters of growth [3]. Group 1: Company Strategy - The acceleration phase represents a continuation and intensification of the strategy to transition Teva from a pure-play generics company to a biopharma company [3]. - The first two years of the strategy focused on returning the company to growth after several years of decline, which has now been achieved [3]. Group 2: Future Focus - The company is now focused on execution over the next 12 to 18 months, emphasizing key aspects of the acceleration phase [2].